NEW YORK, April 2, 2026
PureTech Health plc has announced the publication of its Phase 2b ELEVATE IPF trial results in The American Journal of Respiratory and Critical Care Medicine, highlighting significant progress for deupirfenidone (LYT-100) as a potential next-generation treatment for idiopathic pulmonary fibrosis (IPF). The study demonstrated that deupirfenidone 825 mg TID significantly slowed lung function decline, marking a clinically meaningful advancement in a disease area with limited therapeutic options and high mortality. The findings are expected to accelerate the transition into Phase 3 clinical development, positioning the therapy as a strong candidate to redefine treatment standards in fibrotic lung diseases.
Phase 2b Trial Demonstrates Clinically Meaningful Efficacy
The global, randomized, double-blind ELEVATE IPF trial enrolled 257 patients and evaluated multiple dosing regimens of deupirfenidone against both placebo and active comparator pirfenidone, making it one of the first industry-sponsored studies to include a standard-of-care comparator arm. Results showed that deupirfenidone significantly reduced the rate of forced vital capacity (FVC) decline, with an adjusted mean difference of 91 mL versus placebo (p=0.02) at 26 weeks. Notably, the rate of lung function decline approached levels seen in healthy aging, suggesting a potential paradigm shift in disease management.
The trial also achieved primary and key secondary endpoints, with Bayesian analysis indicating a posterior probability of superiority exceeding 98%, reinforcing statistical robustness and clinical relevance. These outcomes highlight the therapy’s ability to slow disease progression, a critical goal in IPF treatment where lung deterioration is typically irreversible.
Favorable Safety Profile and Improved Drug Exposure
Advertisement
Beyond efficacy, deupirfenidone demonstrated a favorable safety and tolerability profile, comparable to existing therapies, despite achieving approximately 50% greater drug exposure than pirfenidone at the highest approved dose. The incidence of adverse events remained similar between treatment groups, with most events categorized as mild to moderate, supporting its potential for long-term patient adherence. Importantly, 78.1% of patients remained on therapy through 26 weeks, closely matching placebo retention rates, indicating strong tolerability.
Additionally, the study showed a significant delay in disease progression, defined as a ≥5% decline in FVC or death, further reinforcing the drug’s therapeutic potential. These findings collectively suggest that enhanced efficacy does not come at the cost of safety, addressing a long-standing limitation in current antifibrotic treatments.
Pathway to Phase 3 and Future Market Impact
The compelling results from the ELEVATE IPF trial have directly informed the design of the upcoming Phase 3 SURPASS-IPF trial, which will conduct a head-to-head superiority comparison against pirfenidone, the current standard of care. This next phase aims to confirm whether deupirfenidone can deliver superior clinical outcomes, potentially establishing a new benchmark in IPF treatment. With idiopathic pulmonary fibrosis remaining a rare, progressive, and fatal disease with a median survival of two to five years, the need for more effective therapies is urgent.
PureTech’s affiliated entity, Celea Therapeutics, is actively working to secure financing to initiate Phase 3 trials in the first half of 2026, underscoring strong momentum toward commercialization. If successful, deupirfenidone could address not only IPF but also broader fibrotic conditions, significantly expanding its clinical and market potential. The publication in a leading peer-reviewed journal further validates the scientific rigor and translational value of the research, strengthening investor and regulatory confidence.
With robust clinical data, a well-defined regulatory pathway, and the potential to transform outcomes in a high unmet medical need area, deupirfenidone is emerging as a promising breakthrough in respiratory medicine, offering renewed hope for patients suffering from progressive lung fibrosis and positioning PureTech at the forefront of innovative biopharmaceutical development.
Source: PureTech Health press release
